Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO trial (EudraCT 2014-003319-12), we investigate the activity of PARP inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Chopra, Neha, Tovey, Holly, Pearson, Alex, Cutts, Ros, Toms, Christy, Proszek, Paula, Hubank, Michael, Dowsett, Mitch, Dodson, Andrew, Daley, Frances, Kriplani, Divya, Gevensleben, Heidi, Davies, Helen Ruth, Degasperi, Andrea, Roylance, Rebecca, Chan, Stephen, Tutt, Andrew, Skene, Anthony, Evans, Abigail, Bliss, Judith M., Nik-Zainal, Serena, Turner, Nicholas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260192/
https://www.ncbi.nlm.nih.gov/pubmed/32471999
http://dx.doi.org/10.1038/s41467-020-16142-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260192/
https://www.ncbi.nlm.nih.gov/pubmed/32471999
http://dx.doi.org/10.1038/s41467-020-16142-7

Ejemplares similares